Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01416714|
Recruitment Status : Recruiting
First Posted : August 15, 2011
Last Update Posted : May 13, 2021
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy|
|Actual Study Start Date :||July 2, 2008|
|Estimated Primary Completion Date :||January 2025|
|Estimated Study Completion Date :||January 2025|
|Gastrointestinal Stromal Tumors (GIST)|
- Collect and store blood samples [ Time Frame: 1 year ]To collect and store blood samples from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal cancer and colorectal cancer.
- create a database for the collected tissue [ Time Frame: 1 year ]To create a database for the collected tissue and allow access to relevant clinical information for current and future protocols.
- To create tissue microarrays for each gastrointestinal cancer subtype [ Time Frame: 1 year ]To create tissue microarrays for each gastrointestinal cancer subtype, and to facilitate future molecular studies. To grant access to this database (as it is being acquired) of the coupled patient tissue samples (normal and malignant) and relevant clinical information for the investigation of tyrosine kinases, such as Met and Ron, etc., and downstream targets implicated in the pathogenesis of GI cancers. Examples of molecular testing include evaluation of DNA mutation, alternative splice variants, protein expression and phosphorylation, and immunohistochemistry on samples.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01416714
|Contact: Daniel Catenacci, MDemail@example.com|
|Contact: Hedy Kindler, MDfirstname.lastname@example.org|
|United States, Illinois|
|The University of Chicago||Recruiting|
|Chicago, Illinois, United States, 60637|
|Contact: Daniel Catenacci, MD 773-702-7596 email@example.com|
|Principal Investigator: Daniel Catenacci, MD|
|Principal Investigator:||Daniel Catenacci, MD||University of Chicago|